Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • InderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Bolag under bevakning
    • Teamet
Aktieanalys utförd av tredje part

Vitrolife: Getting a good grip on Genetic Services - ABG

Vitrolife

Detta är en aktieanalys producerad av tredje part och reflekterar därför nödvändigtvis ej våra åsikter och värderingar

Ladda ner rapporten (PDF)
Consumables slump signalling bigger slowdown
We cut ‘23e EBIT by 4% on lower growth and margins
Trading at 22x CFY EV/EBITDA (5Y avg. 43x)


On track to lift margins with actions taken in Genetic Services

Vitrolife is delivering on its action plan to increase profitability in Genetic Services. It has discontinued non-core GPDx and Oncology testing, as well as cutting ~20% of the workforce. We expect that it can reach a 30% margin in the long term and 25% already in ‘23e, supporting a long-term group margin in the high 30s. Growth in terms of IVF cycles is slowing down, as shown by consumables sales growing a modest 6% organically, with Americas at +4% and EMEA at -9%. Consumables was 3% below ABGSCe. Technologies also underperformed (-11% vs ABGSCe), with the segment declining 9% organically. Genetic services was the only segment that outperformed, delivering 4% higher sales than we expected. Q3’22 saw the group EBITDA margin (pro forma), adjusted for one-offs in VAT, restructuring and insurance, decline by 2pp vs. Q3’21 to 32.3%. We estimated an EBITDA margin of 33.3%. Considering the one-offs, underlying profitability looks a bit less impressive, although it was 2% better than consensus expectations on 3% better sales. The lower margin mainly stems from the deviation in sales mix, with Genetic Services constituting a larger share of sales than we expected.
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.